beta-D-吡喃葡萄糖基beta-D-吡喃葡萄糖苷 | 499-23-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: beta-D-吡喃葡萄糖基beta-D-吡喃葡萄糖苷
• 英文名称: β,β-trehalose
• 英文别名: Trehalose；β,β'-Trehalose；β,β-tregalose；ββ-trehalose；β-trehalose；beta,beta-Trehalose；(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol
• CAS: 499-23-0
• 化学式: C₁₂H₂₂O₁₁
• 分子量: 342.3
• InChiKey: HDTRYLNUVZCQOY-NCFXGAEVSA-N

物化性质

• 熔点：
  130-135 °C
• 沸点：
  675.4±55.0 °C(Predicted)
• 密度：
  1.76±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  190
• 氢给体数：
  8
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  beta-D-吡喃葡萄糖基beta-D-吡喃葡萄糖苷 在 三甲基氨基磺酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 以20%的产率得到octa-O-sulfonato-β,β-trehalose octasodium salt
  参考文献：
  名称：

  Conformational flexibility in highly sulfated β-d-glucopyranoside derivatives

  摘要：

  Triggered by findings on heparin-like disaccharides, the conformation of sulfated glucopyranosides was investigated. Sodium (methyl 2,3,4-tri-O-sulfonato-beta-D-glucopyranosid)uronate tetrasodium salt is in a conformational equilibrium, to which a non-chair conformation contributes. The same is true for methyl (methyl 2,3,4-tri-O-sulfonato-beta-D-glucopyranosid)uronate trisodium salt, methyl 2,3,4,6-tetra-O-sulfonato-beta-D-glucopyranoside tetrasodium salt, and octa-O-sulfonato-beta,beta-trehalose octasodium salt, with less obvious non-chair contributions. The effect is charge related. The conformational effect, which does not occur in analogous alpha-D-glucopyranoside derivatives, is discussed in terms of the anomeric effect.

  DOI：

  10.1016/0008-6215(95)00131-c
• 作为产物：
  描述：

  2,3,4,6-tetra-O-acetyl-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-1-β-D-glucopyranoside 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 0.25h， 生成 beta-D-吡喃葡萄糖基beta-D-吡喃葡萄糖苷
  参考文献：
  名称：

  衍生自α，α-和β，β-海藻糖的新型水溶性双亚膦酸酯手性配体。在水或水/有机双相介质中脱氢氨基酸及其酯的不对称加氢中的应用。

  摘要：

  新型2,3：4,6-二-O-异亚丙基-α-D-吡喃葡萄糖基-（1,1）-4,6-O-异亚丙基-2,3-二-O-二苯基膦基-α-D-吡喃葡萄糖苷（2），2,3：4,6-二-O-环己叉基-α-D-吡喃葡萄糖基-（1,1）-4,6-O-环己叉基-2,3-二-O-二苯基膦基-α- D-吡喃葡萄糖苷（4）和2,3：4,6-二-O-环己叉基-β-D-吡喃葡萄糖基-（1,1）-4,6-O-环己叉基-2,3-二-O-由相应的α，α-或β，β-海藻糖制备二苯基膦-β-D-吡喃葡萄糖苷（11）。配体被转化为阳离子Rh络合物，例如[Rh（α-D-吡喃葡萄糖基-（1,1）-2,3-二-O-二苯基膦基-α-D-吡喃葡萄糖苷）（cod）] BF（4） （3）和[Rh（β-D-吡喃葡萄糖基-（1,1）-2,3-二-O-二苯基膦基-β-D-吡喃葡萄糖苷）（cod）] BF（4）（12）带有游离羟基。这些络合物可溶于水，是

  DOI：

  10.1021/jo990448m

文献信息

• FLUORESCENT ANTICANCER PLATINUM DRUGS
  申请人：INVICTUS ONCOLOGY PVT. LTD.

  公开号：US20180312534A1

  公开（公告）日：2018-11-01

  The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to fluorescent platinum based compounds. The disclosure further relates to synthesis of said fluorescent platinum based compounds, nanoparticles and compositions comprising said fluorescent platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by the fluorescence changes between aforesaid platinum based compounds and corresponding free ligands, nanoparticles and compositions.

  本公开涉及纳米技术和癌症治疗领域。具体而言，本公开涉及荧光铂基化合物。该公开进一步涉及合成所述荧光铂基化合物、纳米颗粒和包含所述荧光铂基化合物/纳米颗粒的组合物。该公开还涉及通过上述铂基化合物与相应的游离配体、纳米颗粒和组合物之间的荧光变化来管理癌症的方法。
• [EN] TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR_ARMS)<br/>[FR] MOLÉCULES DE RECRUTEMENT D'ANTICORPS CONJUGUÉS À UN AGONISTE DE TLR)
  申请人：UNIV YALE

  公开号：WO2013166110A1

  公开（公告）日：2013-11-07

  The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.

  本发明涉及嵌合化学化合物，用于招募抗体到癌细胞，特别是前列腺癌细胞或转移的前列腺癌细胞。根据本发明的化合物包括一个与细胞结合末端（CBT）和通过连接物和多功能连接组或分子共价结合的抗体结合末端（ABT）基团和Toll样受体激动剂（TLR）。
• CONTINUOUS PROCESSES FOR THE HIGHLY SELECTIVE CONVERSION OF ALDOHEXOSE-YIELDING CARBOHYDRATE TO ETHYLENE GLYCOL
  申请人：Iowa Corn Promotion Board

  公开号：US20170349513A1

  公开（公告）日：2017-12-07

  Continuous processes for making ethylene glycol form aldohexose-yielding carbohydrates are disclosed which enhance the selectivity to ethylene glycol.

  揭示了制备乙二醇形成醛己糖产生的连续过程，这些过程增强了对乙二醇的选择性。
• PROCESS TO PRODUCE 5-HYDROXYMETHYLFURFURAL (HMF) FROM CARBOHYDRATES USING A SOLVENT SYSTEM CONTAINING WATER AND A POLAR APROTIC SOLVENT
  申请人：Wisconsin Alumni Research Foundation

  公开号：US20200039947A1

  公开（公告）日：2020-02-06

  A method to produce 5-hydroxymethylfurfural (HMF) from C6 carbohydrates. The method includes the steps of reacting a reactant comprising at least one C6 carbohydrate, in a reaction mixture comprising at least about 5% (v/v) water, a polar, aprotic solvent, and an acid, for a time, at a temperature, and at a hydrogen ion concentration wherein at least a portion of the C6 carbohydrate present in the reactant is converted to 5-hydroxymethyl furfural (“HMF”).

  一种从C6碳水化合物生产5-羟甲基糠醛（HMF）的方法。该方法包括以下步骤：在反应混合物中，将至少含有一种C6碳水化合物的反应物与至少约5%（体积/体积）水、极性、无水性溶剂和酸反应，反应时间、温度和氢离子浓度使反应物中至少部分的C6碳水化合物转化为5-羟甲基糠醛（“HMF”）。
• [EN] SMALL MOLECULE BASED ANTIBODY-RECRUITING COMPOUNDS FOR CANCER TREATMENT<br/>[FR] COMPOSÉS DE RECRUTEMENT D'ANTICORPS À BASE DE PETITES MOLÉCULES POUR LE TRAITEMENT DU CANCER
  申请人：UNIV YALE

  公开号：WO2017023994A1

  公开（公告）日：2017-02-09

  The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.

  本发明涉及嵌合（包括双功能）化合物，包含这些化合物的组合物以及治疗患者或受试者癌症的方法，特别是包括转移性癌症，其中癌细胞相对于正常（非癌细胞）细胞表现出细胞表面尿激酶型纤溶酶原激活剂受体（尿激酶受体）的过表达（增强表达）。这些化合物与癌细胞表面的尿激酶型纤溶酶原激活剂受体（uPAR）结合，包括转移性癌细胞，从而招募患者或受试者的天然抗体，这些抗体可以通过抗体依赖性细胞吞噬和抗体依赖性细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）选择性地降解和/或使靶向的癌细胞失活，针对大量和各种癌症，从而提供癌细胞死亡并抑制癌症的生长、扩散和/或转移，包括患者癌症的缓解和治愈。